These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31426543)

  • 1. Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment-A Systematic Literature Review.
    Batko B; Rolska-Wójcik P; Władysiuk M
    Int J Environ Res Public Health; 2019 Aug; 16(16):. PubMed ID: 31426543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying the economic burden of productivity loss in rheumatoid arthritis.
    Filipovic I; Walker D; Forster F; Curry AS
    Rheumatology (Oxford); 2011 Jun; 50(6):1083-90. PubMed ID: 21245074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study.
    Tanaka Y; Yamazaki K; Nakajima R; Komatsu S; Igarashi A; Tango T; Takeuchi T
    Mod Rheumatol; 2018 Jan; 28(1):39-47. PubMed ID: 28704126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
    Hsieh PH; Wu O; Geue C; McIntosh E; McInnes IB; Siebert S
    Ann Rheum Dis; 2020 Jun; 79(6):771-777. PubMed ID: 32245893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid arthritis and work: The impact of rheumatoid arthritis on absenteeism and presenteeism.
    Verstappen SM
    Best Pract Res Clin Rheumatol; 2015 Jun; 29(3):495-511. PubMed ID: 26612244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
    Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
    Hu H; Luan L; Yang K; Li SC
    Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.
    Hone D; Cheng A; Watson C; Huang B; Bitman B; Huang XY; Gandra SR
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1564-72. PubMed ID: 23554320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs.
    Ghabri S; Lam L; Bocquet F; Spath HM
    Pharmacoeconomics; 2020 May; 38(5):459-471. PubMed ID: 32052376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Productivity cost model of the treatment of rheumatoid arthritis with abatacept.
    Burton WN; Morrison A; Yuan Y; Li T; Marioni RE; Maclean R
    J Med Econ; 2008; 11(1):3-21. PubMed ID: 19450107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.
    Birnbaum H; Pike C; Kaufman R; Cifaldi M
    J Occup Environ Med; 2009 Oct; 51(10):1167-76. PubMed ID: 19786900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect costs of rheumatoid arthritis in Brazil.
    de Azevedo AB; Ferraz MB; Ciconelli RM
    Value Health; 2008; 11(5):869-77. PubMed ID: 18489511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
    Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical and economic aspects of rheumatoid arthritis].
    Fautrel B; Gaujoux-Viala C
    Bull Acad Natl Med; 2012 Oct; 196(7):1295-305; discussion 1305-6. PubMed ID: 23815015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Schoels M; Wong J; Scott DL; Zink A; Richards P; Landewé R; Smolen JS; Aletaha D
    Ann Rheum Dis; 2010 Jun; 69(6):995-1003. PubMed ID: 20447950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.